Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
about
Successes and Challenges of PARP Inhibitors in Cancer TherapyFifteen years of irinotecan therapy for pediatric sarcoma: where to next?Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic LandscapesRecent advances in targeted therapy for Ewing sarcomaSLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.The facile construction of the phthalazin-1(2H)-one scaffold via copper-mediated C-H(sp(2))/C-H(sp) coupling under mild conditions.Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiencyDelineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of GlioblastomaPARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.PARP inhibitors as antitumor agents: a patent update (2013-2015).Identifying novel therapeutic agents using xenograft models of pediatric cancer.PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs.Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.Development and validation of a high-performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studies.Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells.Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies
P2860
Q26777131-3F13911D-3CF3-45BD-B1EA-66804BD16F66Q26795742-1FF27AD1-BFC0-4F17-AC3B-2691A5CC382CQ26801785-B4CA97B7-B8E0-4DE8-8F52-54A17F91981AQ28079316-F1DB7D83-B48E-439F-B069-E5375820A087Q36069053-88E04C9A-C51A-407D-9B34-2C6EE71FAD3AQ36257738-820FDDD1-771F-416E-9FFB-44999A8AF528Q36322179-5185EB18-7FE3-4432-8A43-16367D149FACQ36392466-8F8D103B-FB5D-4C19-92B8-AC2854332A39Q36887663-BDD0894F-4949-4137-9DBA-2D1996F4C43FQ37607283-A4C16271-7F3A-4C6C-A781-6A09E4483312Q37656224-A67C0318-B43F-488C-8190-C0A9571304FFQ37684589-FB341C53-56B6-4E33-AAAC-0C7DDDA0BE3FQ38405687-3EA26E2C-D99A-4FE0-9BF0-72B0498DF4B4Q38683171-536CB631-3C8B-408F-9B38-B010B0ADAF65Q38753542-CF691F30-6E84-4A38-B33C-B88AF774EC36Q38795712-4E9AA80E-85B6-4445-93FC-2BC0E0167AF1Q38837564-ED6BE12E-C257-4123-8014-87CB54E0D779Q40640808-009F5ABA-B7FB-4E05-9FAF-F6A40040A8EAQ43042008-F0C29F34-8D50-4835-AB4D-9E287CD5592FQ45973213-14443FEF-6926-44CE-A86F-C377FC9569A8Q46097861-E95F43CC-EF02-4E02-AB21-7D097D238AAFQ47710977-D91E4E7A-DED5-4810-9C82-2FCC3415171FQ48290610-F188EDA1-9656-43C0-834D-1E60E993000DQ52604402-5BD4729F-C1B8-42F4-8B6B-4F99F2918845Q55037005-3785F080-7455-438F-B816-14654A2C30AAQ59128454-F539C96D-881A-43E1-AD4A-FD537B90CA0D
P2860
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Synergistic activity of PARP i ...... c preclinical testing program.
@ast
Synergistic activity of PARP i ...... c preclinical testing program.
@en
type
label
Synergistic activity of PARP i ...... c preclinical testing program.
@ast
Synergistic activity of PARP i ...... c preclinical testing program.
@en
prefLabel
Synergistic activity of PARP i ...... c preclinical testing program.
@ast
Synergistic activity of PARP i ...... c preclinical testing program.
@en
P2093
P2860
P50
P1476
Synergistic activity of PARP i ...... ic preclinical testing program
@en
P2093
C Patrick Reynolds
Catherine A Billups
Dmitry Lyalin
E Anders Kolb
Hernan Carol
John M Maris
Peter J Houghton
Raushan T Kurmasheva
Stephen T Keir
P2860
P304
P356
10.1158/1078-0432.CCR-14-2572
P407
P577
2014-12-10T00:00:00Z